APRI - Apricus Biosciences, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.2905
-0.0096 (-3.20%)
At close: 4:00PM EDT

0.2905 0.00 (0.00%)
After hours: 4:39PM EDT

Stock chart is not supported by your current browser
Previous Close0.3001
Open0.3150
Bid0.2905 x 3100
Ask0.3000 x 2900
Day's Range0.2900 - 0.3150
52 Week Range0.2500 - 3.3400
Volume358,775
Avg. Volume950,261
Market Cap6.81M
Beta0.74
PE Ratio (TTM)10.76
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Associated Press20 days ago

    Apricus: 1Q Earnings Snapshot

    On a per-share basis, the San Diego-based company said it had a loss of 14 cents. In the final minutes of trading on Thursday, the company's shares hit 26 cents. A year ago, they were trading at $1.16. ...

  • Benzingalast month

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Netflix, Inc. (NASDAQ: NFLX ) stock was trading higher ...

  • Reuterslast month

    Apricus mulls options; to sell U.S. rights to Vitaros

    Apricus Biosciences Inc said on Monday it was considering options for the company and looking to sell the U.S. rights to its erectile dysfunction cream Vitaros, after the Food and Drug Administration asked it to make a new formula for the product. Shares of the company fell 24 percent to 32 cents in premarket trading, valuing the company at $7.5 million.

  • Reuterslast month

    FDA asks for new formulation of Apricus' erectile dysfunction cream

    Drugmaker Apricus Biosciences Inc said on Monday the U.S. regulator directed it to develop a new formulation for its erectile dysfunction cream, Vitaros, which was rejected in February. The U.S. Food And ...

  • Market Exclusive2 months ago

    Edge Therapeutics And Apricus Biosciences Are Moving: Here’s Why

    Edge Therapeutics, Inc. (NASDAQ:EDGE) is grabbing all of the headlines in the biotechnology space heading into the close of this week on news that a trial rooted in one of its lead development assets has failed to hit the mark. The trial in question was looking at a drug called EG-1962. This is one of […] The post Edge Therapeutics And Apricus Biosciences Are Moving: Here’s Why appeared first on Market Exclusive.

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of APRI earnings conference call or presentation 1-Mar-18 9:30pm GMT

    Q4 2017 Apricus Biosciences Inc Earnings Call

  • Associated Press3 months ago

    Apricus reports 4Q loss

    On a per-share basis, the San Diego-based company said it had a loss of 16 cents. In the final minutes of trading on Thursday, the company's shares hit 87 cents. A year ago, they were trading at $2.88. ...

  • At $0.9401, Is Apricus Biosciences Inc (NASDAQ:APRI) A Buy?
    Simply Wall St.3 months ago

    At $0.9401, Is Apricus Biosciences Inc (NASDAQ:APRI) A Buy?

    Apricus Biosciences Inc (NASDAQ:APRI), a pharmaceuticals company based in United States, received a lot of attention from a substantial price movement on the NasdaqCM in the over the last fewRead More...

  • Benzinga3 months ago

    Attention Biotech Investors: Mark Your Calendar For These March PDUFA Dates

    The FDA decided favorably on four of the six major PDUFA decisions due in February , with Valeant Pharmaceuticals Intl Inc (NYSE: VRX )'s Salix Pharma unit and its partner Norgine announcing an extension ...

  • Apricus Biosciences (APRI) Soars: Stock Adds 8.6% in Session
    Zacks3 months ago

    Apricus Biosciences (APRI) Soars: Stock Adds 8.6% in Session

    Shares of Apricus Biosciences (APRI) rose about 9% yesterday.

  • Market Exclusive3 months ago

    Here’s What’s Moving Apricus Biosciences And Pacira Pharmaceuticals

    Apricus Biosciences, Inc. (NASDAQ:APRI) is an early mover in the biotechnology space this week, with the company putting out an update on a regulatory development from its lead development asset. Unfortunately, for both the company and its shareholders, the update lands squarely on the negative end of the spectrum. So what happened? Apricus just reported […] The post Here’s What’s Moving Apricus Biosciences And Pacira Pharmaceuticals appeared first on Market Exclusive.

  • Benzinga3 months ago

    What's Next For Apricus Biosciences' Vitaros?

    Apricus Biosciences Inc (NASDAQ: APRI ) receded 67.4 percent Friday and continued down Tuesday after the U.S. Food and Drug Administration issued a response letter for Vitaros. The FDA declined to approve ...

  • Interested In Apricus Biosciences Inc (NASDAQ:APRI)? Here’s What Its Recent Performance Looks Like
    Simply Wall St.3 months ago

    Interested In Apricus Biosciences Inc (NASDAQ:APRI)? Here’s What Its Recent Performance Looks Like

    In this commentary, I will examine Apricus Biosciences Inc’s (NASDAQ:APRI) latest earnings update (30 September 2017) and compare these figures against its performance over the past couple of years, asRead More...

  • Is It “Game Over” After Apricus Biosciences Inc (APRI) FDA Rejection?
    SmarterAnalyst3 months ago

    Is It “Game Over” After Apricus Biosciences Inc (APRI) FDA Rejection?

    Apricus Biosciences Inc (NASDAQ:APRI) shares are collapsing today, down nearly 65%, following the news that the FDA has issued the company a complete response letter, rather than a green light to begin marketing its topical erectile dysfunction (ED) drug Vitaros. The CRL indicates that the FDA cannot approve the NDA for Vitaros in its present form, identifying deficiencies related to Chemistry, Manufacturing and Control (CMC) and certain safety concerns specific to the 2.5% concentration of DDAIP.HCl contained in the current formulation. Apricus CEO Richard W. Pascoe commented, "We are disappointed with the outcome of the review given the substantial amount of CMC, clinical and non-clinical data and analysis provided to the FDA in the Vitaros resubmission.

  • Reuters3 months ago

    Shares of Apricus tank after FDA declines to OK erectile dysfunction cream

    The U.S. Food and Drug Administration on Friday declined to approve Apricus Biosciences Inc's Vitaros, a cream to treat erectile dysfunction, for the second time in a decade, sending the company's shares down more than 70 percent before the opening bell. The drugmaker was hoping to sell Vitaros, possibly through commercial partner Allergan Plc, to patients unable to use oral medications and also looking for less invasive existing options.

  • Benzinga3 months ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! The Coca-Cola Co (NYSE: KO ) stock was trading higher ...

  • Should You Buy Apricus Biosciences Inc (APRI) Now?
    Simply Wall St.6 months ago

    Should You Buy Apricus Biosciences Inc (APRI) Now?

    Apricus Biosciences Inc (NASDAQ:APRI), a pharmaceuticals company based in United States, saw significant share price volatility over the past couple of months on the NasdaqCM, rising to the highs ofRead More...

  • Thomson Reuters StreetEvents6 months ago

    Edited Transcript of APRI earnings conference call or presentation 2-Nov-17 8:30pm GMT

    Q3 2017 Apricus Biosciences Inc Earnings Call

  • Associated Press7 months ago

    Apricus reports 3Q loss

    The San Diego-based company said it had a loss of 29 cents per share. Losses, adjusted to account for discontinued operations, came to 30 cents per share. In the final minutes of trading on Thursday, the ...

  • Should You Be Concerned About Apricus Biosciences Inc’s (APRI) Risks?
    Simply Wall St.7 months ago

    Should You Be Concerned About Apricus Biosciences Inc’s (APRI) Risks?

    For Apricus Biosciences Inc’s (NASDAQ:APRI) shareholders, and also potential investors in the stock, understanding how the stock’s risk and return characteristics can impact your portfolio is important. Every stock inRead More...

  • Thomson Reuters StreetEvents9 months ago

    Edited Transcript of APRI earnings conference call or presentation 2-Aug-17 8:30pm GMT

    Q2 2017 Apricus Biosciences Inc Earnings Call

  • Associated Press10 months ago

    Apricus reports 2Q loss

    The San Diego-based company said it had a loss of 13 cents per share. Losses, adjusted to account for discontinued operations, came to 15 cents per share. In the final minutes of trading on Wednesday, ...